SEC Contract Filing

Filing Date: 2017-05-03

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>htbx_ex10z2.htm
<DESCRIPTION>LICENSE AGREEMENT
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>LICENSE AGREEMENT</TITLE>
<META NAME="author" CONTENT="Administrator">
<META NAME="date" CONTENT="04/28/2017">
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<P style="margin:0px"><B>Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.&nbsp;&nbsp;A complete copy of this document has been filed separately with the Securities and Exchange Commission.</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:10.667px; font-size:12pt" align=right><B>EXHIBIT 10.2</B></P>
<P style="margin-top:0px; margin-bottom:10.667px; font-size:12pt" align=center><B><U>LICENSE AGREEMENT</U></B></P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">This License Agreement (the &quot;Agreement&quot;) is entered into and made effective the 11th day of July, 2008 (the &quot;Effective Date&quot;) between UNIVERSITY OF MIAMI &nbsp;and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida &nbsp;33136 (hereinafter referred to as &quot;LICENSOR&quot;) and HEAT BIOLOGICS II, INC., a Delaware &nbsp;corporation, whose principal place of business is at Atlantic Center, 119 Washington Avenue, Suite 401, Miami Beach, FL 33139 (hereinafter referred to as &quot;LICENSEE&quot;).</P>
<P style="margin-top:0px; margin-bottom:10.667px; font-size:12pt" align=center>WITNESSETH</P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">WHEREAS, LICENSOR is the sole owner of the technology and product identified as the Podack Antibody Technology (UM03-31, UM05-39);</P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">WHEREAS. LICENSOR is the sole owner of the patent rights relating to the Podack Antibody Technology (UM03-31, UM05-39); </P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">WHEREAS LICENSOR wishes to exclusively license to LICENSEE the Podack Antibody Technology (UM03-31, UM05-39) and patent rights related thereto; and </P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">WHEREAS, LICENSEE desires to acquire an exclusive license from LICENSOR to the Podack Antibody Technology (UM03-31, UM05-39) and patent rights related thereto for the purpose or commercially marketing the Podack Antibody Technology (UM03-31, UM05-39). </P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:96px; font-size:12pt">NOW THEREFORE, for these and other valuable considerations. the receipt of which is hereby acknowledged, the parties agree as follows: </P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:96px; width:144px; font-size:12pt; float:left"><B>1.</B></P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:-2px; font-size:12pt"><B>DEFINITIONS:</B></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:96px; width:144px; font-size:12pt; clear:left; float:left">1.1</P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:-2px; font-size:12pt">&quot;Affiliate&quot; shall mean any corporation or other business entity controlled by, controlling or under common control with LICENSEE. &nbsp;For this purpose, &quot;control&quot; shall mean direct or indirect beneficial ownership of at least a fifty percent (50%) of the voting stock of, or at least a fifty percent (50%) interest in the income of such corporation or other business entity, or such other relationship as in fact, constitutes actual control.</P>
<P style="margin-top:0px; margin-bottom:10.667px; clear:left"><BR>
<BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-right:24px" align=center>Page 1 of 20</P>
<P style="margin:0px"><BR></P>
<HR style="margin-bottom:9.6px; padding-top:9.6px" noshade size=1.333>
<P style="margin:0px; page-break-before:always"><B>Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.&nbsp;&nbsp;A complete copy of this document has been filed separately with the Securities and Exchange Commission.</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:96px; width:144px; font-size:12pt; float:left">1.2</P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:-2px; font-size:12pt">&quot;Sublicensee&quot; as used in this Agreement shall mean any third party to whom LICENSEE has granted a license to make, have made, use and/or sell the Product under the Patent Rights, provided said third party has agreed in writing with LICENSEE to accept the conditions and restrictions agreed to by LICENSEE in this Agreement.</P>
<P style="margin-top:0px; margin-bottom:-2px; text-indent:96px; width:144px; font-size:12pt; clear:left; float:left">1.3</P>
<P style="margin-top:0px; margin-bottom:10.667px; text-indent:-2px; font-size:12pt">&quot;Patent Rights&quot; shall mean the following United States Patent applications: &nbsp;U.S. patent application serial number 10/923,373 entitled &#145;COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY LUNG DISEASE&#148; and filed on August 24, 2004; US Provisional Patent Applications series lumbers 60/496,555 and 60/496,625 both filed on August 20, 2003; US Patent Application serial number 11/512,412 entitled &#147;IMMUNOMODULATING TUMOR NECROSIS FACTOR FOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS AND IMMUNOTOXINS&#148; and filed on August 30, 2006; US Provisions Patent Application serial number 60/712,084 filed on August 30, 2005; all United States Patents and foreign patents and paten